Incidence of Secondary Cancer Development After High-Dose Intensity-Modulated Radiotherapy and Image-Guided Brachytherapy for the Treatment of Localized Prostate Cancer

Late rectal toxicity after low-dose-rate brachytherapy: Incidence, predictors, and management of side effects

“…However, two other large singleinstitution studies have recently challenged these findings. Zelefsky et al (72) did not identify an increased risk of secondary malignancy in a cohort of 1310 patients who underwent either EBRT or BT for prostate cancer, as compared with the general population. Hamilton et al (73) similarly did not find a higher rate of secondary malignancies in a cohort of 2418 patients treated with BT, compared with a group of 4015 patients treated with radical prostatectomy.…”

The Anti-Cancer Effect of Watercress (Rorripa Nasturtium Aquaticum) Extract on Breast Cancer Cells

“…But, these methods are costly and they have some destructive side effects on human body [4][5][6][7]. Therefore, requirement for an efficient, low cost, and less dangerous method is sensed.…”

Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer

“…3, and three single institution studies [17][18][19] found that the risk of rectal cancer following brachytherapy monotherapy or combination brachytherapy and external beam radiotherapy (BT-EBRT) was no higher than that in the general population. The risk of bladder cancer after brachytherapy monotherapy was also found to be no different to that in the general population in one SEER registry study though there was an increased risk in patients who received combination BT-EBRT [16].…”

“…The risk of bladder cancer after brachytherapy monotherapy was also found to be no different to that in the general population in one SEER registry study though there was an increased risk in patients who received combination BT-EBRT [16]. Two single institution studies, one examining brachytherapy monotherapy and one examining combination BT-EBRT and brachytherapy monotherapy found no significant difference in the risk of bladder cancer compared to the general population [18,19]. In contrast, two other single institution studies, one examining a mixed population of brachytherapy monotherapy and BT-EBRT patients, and one examining only brachytherapy monotherapy patients, found these patients to be at increased risk of bladder cancer compared to the general population [17,20].…”